



EPICOR® POSTBIOTIC RESEARCH

New study finds the body responds to EpiCor® postbiotic within hours


EpiCor® postbiotic has published 15+ studies exploring its role in immune and digestive health to help people live more healthy days.™ The newest research shows that after a single serving, the body exhibits measurable changes in immune-related markers, offering a new window into how quickly EpiCor® interacts with the immune system.

What the new research showed:

- **Fast-acting** — Changes in immune-related markers appeared within one to three hours, compared to the placebo.
- **Single serving** — The effect followed a single, 500mg serving of EpiCor® postbiotic.
- **Targeted response** — The changes were selective and coordinated: targeted modulation without generalized immune suppression.

These changes occurred without broad immune suppression, suggesting targeted modulation of immune responses initiated at the gut mucosa level after ingestion of the postbiotic, and triggering systemic effects.”

EpiCor® postbiotic rapid immune response study design



About the study:

Thirty healthy adults (16 men/14 women) received a 500mg serving of EpiCor® postbiotic or placebo, then switched to the other selection after a one-week break. Blood was drawn before consumption, and again at one, two and three hours post-consumption.

What researchers observed:

- **A single serving of EpiCor® induced rapid, coordinated changes** in immune-related biomarkers compared to placebo.
- **Within one hour, significant changes** in interferon-gamma (IFN-g) and interleukin-1ra levels (IL-1ra) were observed compared to placebo ($P \leq 0.05$).
- **By the two-hour mark, three more shifted significantly:** IL-4, IL-7, and IL-8 ($P \leq 0.05$).
- **The pattern was selective among these proteins** which help immune cells communicate, rather than across the board.

What it means:

There are early, measurable biomarker changes that provide a look at how EpiCor® works in the short-term, to add to the immune and digestive research already conducted with longer-term studies.

Why formulators choose EpiCor® postbiotic:

EpiCor® is a non-living, stable postbiotic that works across a wide range of formats without refrigeration. It is backed by more than 15 published studies, including research in adults and children. A low, 500mg clinically studied daily serving amount makes it easy to build into everyday products like beverages, bars, gummies and stick packs.



Harness the possibilities of EpiCor® postbiotic.

To learn more, contact your Cargill representative or visit cargill.com.

Frontiers in Nutrition. "A Yeast-Derived Postbiotic Fermentate Rapidly Modulates Inflammatory Cytokines and Immune Surveillance Markers in Healthy Adults: A Randomized Double-Blind Placebo-Controlled Cross-Over Trial." August 5, 2026. <https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2026.1897550/full>

EpiCor® is not intended to diagnose, treat, cure, or prevent any disease. Claims and usage levels may vary by region and must comply with local regulatory requirements. Clinical substantiation available upon request.

All information, statements, recommendations, and suggestions are believed to be true and accurate but are made without guarantee, express or implied. We disclaim all warranties, express or implied, and disclaim all liability in connection with the use of our products or information, statements, recommendations, and suggestions contained herein. The labeling, substantiation and decision making relating to the claims for your products is your responsibility. We recommend you consult regulatory and legal advisors prior to making regulatory, labeling or claims decisions for your products.